Siolta Therapeutics Achieves Promising Phase 2 Results for STMC-103H in Preventing Allergic Diseases Siolta Therapeutics has announced encouraging Phase 2 results for STMC-103H, showing significant potential in preventing allergic diseases in at-risk infants.

Siolta Therapeutics Achieves Promising Phase 2 Results for STMC-103H in Preventing Allergic Diseases #USA #San_Carlos #Siolta_Therapeutics #STMC-103H #ADORED_Study